Research programme: anaemia therapeutics - Palkion

Drug Profile

Research programme: anaemia therapeutics - Palkion

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator CrystalGenomics; Palkion
  • Developer Palkion
  • Class DNA-binding proteins
  • Mechanism of Action Procollagen-proline dioxygenase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in USA (PO)
  • 28 May 2010 CrystalGenomics has merged with BexPharm
  • 29 Jun 2009 Preclinical trials in Anaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top